9 December 2016
MMJ Observer reports on a future possible colloboration between the Harvard Medical School & Cannabis Science Inc
Harvard Medical School Shows Willingness For Future Partnership With Cannabis Science Inc (OTCMKTS: CBIS)
The Global Health Catalyst’s Harvard Director recently showed its interest in a future partnership with Cannabis Science Inc (OTCMKTS: CBIS). The company gave a presentation to the Harvard Medical School, which was admired by Dr. Wilfred F. Ngwa, the Global Health Catalyst Director. Praising the presentation of the company, Dr. Wilfred F. Ngwa said that this might “lead to mutually beneficial partnership opportunities” between Harvard Medical School & the company.
Other alternatives to medicine
Acceptance and appraisal of Cannabis’ presentation seems important; especially when the U.S. has been debating over legalizing medical and recreational marijuana of late. In the light of this development, the partnership interest of Global Health Catalyst Director in the company’s plans ahead seems interesting. This is so because Global Health Catalyst Director is a world known Harvard Cancer Center.
So does all this indicate that the world is ready to look at the alternatives to medicine, in the form of medical cannabis?
Commenting on the company’s presentation, Dr. Wilfred F. Ngwa said that the company’s knowledge and clarity of mission was a refreshing change in the industry. He said that the partnership between the two entities might possibly bring out the potential of cannabinoids in treating the deadly cancer disease, along with other severe illnesses.
He highlighted that a detailed medical journal reviewed by concerned peer shall be released and published soon.
The presentation of the company focussed largely on cannabinoids science and its ability to combat cancer by killing such cells. Therapeutic management of this fatal disease was discussed by the company. Dr. Allen A. Herman, CMO of Cannabis Science gave a detailed presentation on the company, its products and Cannabis Science Research Foundation.
His discussions focussed on clinical research programs and pre-clinical trials for the future prospects. The partnership between the company and Harvard Medical Schools seems to be bringing a paradigm transition in phyto-pharmaceutical development.
